Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease

Michael Saadeh, Apoorva Krishna Chandar, Sadeer Al-Kindi, Vu Quang Nguyen, Revital Gorodeski Baskin, Jeffry Katz, Fabio Cominelli, Miguel Regueiro, Emad Mansoor

Research output: Contribution to journalReview articlepeer-review

Abstract

Patients with IBD are at an increased risk of major adverse cardiovascular events (MACE), potentially due to both atherosclerotic and non-atherosclerotic, inflammation- mediated pathways. In this retrospective cohort study, IBD patients with GLP-1RA use were less likely to have MACE.

Original languageEnglish (US)
Article numberotaf056
JournalCrohn's and Colitis 360
Volume7
Issue number3
DOIs
StatePublished - Jul 1 2025

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this